A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Phase 1 Completed 36 enrolled Kartos Therapeutics, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.

Evaluation	Drug	Modality	Dose	Route
Subject	Navtemadlin	Small molecule	60 mg	Oral
Subject	Navtemadlin	Small molecule	120 mg	Oral
Subject	Navtemadlin	Small molecule	240 mg	Oral
Subject	Navtemadlin	Small molecule	360 mg	Oral
Subject	Navtemadlin	Small molecule	480 mg	Oral
Subject	Navtemadlin	Small molecule	960 mg	Oral
Subject	Trametinib	Small molecule	2 mg	Oral